SCHEMBL26554307

SCHEMBL26554307

CC(C)(C)OC(=O)NCCNc1nc2ccc(Br)cc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.46
LCK P06239 1/20 0.45
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HIF1A Q16665 1/20 0.41
LATS1 O95835 1/20 0.41
BRD4 O60885 6/20 0.40
SUV39H2 Q9H5I1 2/20 0.40
MALT1 Q9UDY8 1/20 0.40
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
EGFR P00533 1/20 0.38
RAF1 P04049 1/20 0.38
KDR P35968 1/20 0.38
MAP2K2 P36507 1/20 0.38
MAP2K1 Q02750 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26554310 0.94 STK17B (0.44) BCHELCKKDM4EALDH1A1GLA
SCHEMBL26554263 0.91 BCHE (0.46) BCHELCKKDM4EALDH1A1GLA
SCHEMBL29437012 0.85 USP2 (0.43) BRD4USP2LMNA
SCHEMBL26554279 0.85 STK17B (0.44) BCHEKDM4EALDH1A1GLAGAA
SCHEMBL29437026 0.85 STK17B (0.44) BCHEKDM4EALDH1A1GLAGAA
SCHEMBL26554281 0.85 USP2 (0.43) BRD4USP2LMNA
SCHEMBL26554287 0.84 USP2 (0.44) KDM4EMAPTBRD4USP2LMNA
SCHEMBL29437062 0.84 USP2 (0.44) KDM4EMAPTBRD4USP2LMNA
SCHEMBL1980682 0.84 BCHE (0.58) BCHELCKKDM4EALDH1A1GLA
SCHEMBL29437074 0.83 HTT (0.47) KDM4EALDH1A1GLAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-10-19 US disclosed
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-10-19 US disclosed
EP-4211111-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2023-07-19 EP disclosed
WO-2022056045-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 BCHE 1326/4885LCK 3745/4885KDM4E 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.